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Myocardial involvement is an important prognostic factor in patients with systemic sclerosis, and early diagnosis and staging of
the disease have been sought after. Since myocardial damage is characterized by connective tissue disease, including ﬁbrosis and
diﬀuse vascular lesions or microcirculation, nuclear myocardial perfusion imaging has been a promising option for evaluating
myocardial damages in early stages. In addition to the conventional stress-rest perfusion imaging, the current use of quantitative
electrocardiographic gated imaging has contributed to more precise evaluation of cardiac perfusion, ventricular wall motion, and
diastolic function, all of which have enhanced diagnostic ability of evaluating myocardial dysfunction. Abnormal sympathetic
imaging with Iodine-123 metaiodobenzylguanidine might be another option for identifying myocardial damage. This paper
deals with approaches from nuclear cardiology to detect perfusion and functional abnormality as an early sign of myocardial
involvement as well as possible prognostic values in patients with abnormal imaging results. The role of nuclear cardiology in the
era of multiple imaging modalities is discussed.
1.Introduction
Systemic sclerosis (SSc) is a connective tissue disease char-
acterized by diﬀuse vascular lesions and ﬁbrosis, and it
systemically involves various organs such as skin (sclero-
derma), heart, lung, kidney and gastrointestinal tracts [1–6].
Of these organ involvements, cardiac complications include
arrhythmias, pericarditis, angina pectoris, congestive heart
failure and sudden death. Autopsy ﬁndings demonstrated
that myocardial ﬁbrosis in SSc has been a common occur-
rence [1, 7]. Thus, it has become evident that early diagnosis
andaccuratestagingofvisceralinvolvementarefundamental
for appropriate management and therapeutic approaches
for SSc [8]. These approaches may provide a signiﬁcant
prognostic value to systemic sclerosis. Although the precise
mechanism for pathogenesis and etiology is not the aim
of this article, nuclear medicine approaches to SSc patients
are presented in this paper. The mechanisms of cardiac
dysfunction and insight that can be gained from nuclear
imaging are discussed.
2. Subsetsof SScandOrgan Involvements
SScisusuallyclassiﬁedintotwosubsetsofdiﬀuseandlimited
cutaneous types (dcSSc and lcSSc) [3]. The major ﬁndings
of skin sclerosis and organ involvement are summarized in
Table 1. Common manifestations of organ involvement in
dcSSc include interstitial lung disease, renal failure, diﬀuse
gastrointestinal disease, and myocardial involvement. It has
been found that cardiac involvement is more common in
patients with dcSSc, and one of the least predictable of the
visceral involvements during the clinical course of dcSSc.
However, even in the lcSSc subset, ischemic response has
been detected in 64% of the patients using thallium-201
(201Tl) myocardial perfusion imaging [9]. A research group
database from the EULAR scleroderma trials showed that
scleroderma subsets (lcSSc and dcSSc types), autoantibody
status and age at onset of Raynaud’s phenomenon were
found to be independently associated with the prevalence of
organ manifestations [10]. It was also important to separate
patients into two SSc subsets for the purpose of survival2 International Journal of Rheumatology
analysis. Poorer prognosis was associated with the dcSSc
type, positive antitopoisomerase I antibody and negative
anticentromere antibody in the long-term followup [11–13].
3. Nuclear Cardiology Studiesfor
CardiacInvolvementinSSc and
Pathophysiological Bases
3.1. Myocardial Perfusion Imaging and Underlying Pathophys-
iology. In nuclear cardiology, myocardial perfusion imaging
has been used extensively for evaluating coronary artery
disease, which includes diagnosis of ischemic heart disease,
physiological assessment of known coronary stenosis, viabil-
ity assessment after acute coronary syndrome, reevaluation
after coronary intervention, and risk stratiﬁcation for future
cardiac events [14]. The diagnostic sensitivity of coronary
artery disease is approximately 80%–90%, and its speciﬁcity
is around 70%–80%. The advent of electrocardiography
(ECG) gated perfusion imaging has further enhanced diag-
nostic accuracy by simultaneously evaluating myocardial
ischemia and functional abnormality [15].
Inmorethanthreedecadesofhistoryofnuclearmedicine
in cardiology, an early ﬁnding of myocardial perfusion
abnormality in SSc was documented in 1984 by planar 201Tl
perfusion imaging with circumferential proﬁle analysis that
added quantitative support [16, 17]. Coronary angiography
was normal in those patients. A reduced coronary ﬂow
reservehasalsobeendocumentedwithoutcoronarystenosis.
A subsequent study using cold-stress showed transient
myocardial perfusion defects as visualized by 201Tl [18]. The
authors suggested that cold exposure in SSc patients might
elicit transient reﬂex coronary vasoconstriction resulting in
reversible myocardial ischemia and dysfunction. Using cold
stress and dipyridamole stress, half of the patients with
long-standing Raynaud’s phenomenon presented ischemic
201Tl defects [19]. It is noteworthy that scleroderma patients
with a normal dipyridamole test demonstrated cold-induced
transient myocardial ischemia. Thus, primary involvement
is not major coronary artery stenosis in SSc, but the target
of perfusion abnormality is related to microcirculation.
Despite the potential diﬀerences in imaging targets, nuclear
medicine studies with 201Tl and Technetium-99m (99mTc)-
labeled radiopharmaceuticals have shown that either stress-
induced ischemia or persistent perfusion defects occur in SSc
patients [18–24]. After the advent of single-photon emission
computed tomography (SPECT), the detectability of small
perfusiondefectswasenhanced. Astudy with 201TlSPECTin
patients with SSc and systemic lupus erythematosus showed
a high incidence of (82%) of abnormal ﬁndings by 201Tl
SPECT [25]. The authors used quantitative analysis with
a polar map and a 17-segment model, and found reverse
redistribution ﬁnding in patients with collagen diseases.
Based on a pathophysiological viewpoint, abnormalities
of microcirculation seemed to play an important role
leadingtomyocardialdamages[16].Focalmyocardiallesions
ranging from contraction band necrosis to ﬁbrosis and
reversible vasospastic abnormality in small coronary arteries
have been found to be a key mechanism in myocardial
Table 1: SSc subsets and organ involvements.
Diﬀuse cutaneous SSc Limited cutaneous
SSc
Skin sclerosis Truncal and acral skin
involvement
Limited to hands,
feet, face, and
forearms, or absent
Organ
involvement
Early and signiﬁcant
incidence of
interstitial lung
disease, oliguric renal
failure, diﬀuse
gastrointestinal
disease, and
myocardial
involvement
Signiﬁcant late
incidence of
pulmonary
hypertension,
trigeminal neuralgia,
calcinosis, and
teleangiectasia
Antibodies
Anti-DNA
topoisomerase I
antibodies
Anticentromere
antibodies
dysfunction. Patchy scarring and focal necrosis unassociated
with coronary artery disease were observed, and pathologic
changes were sometimes associated with ﬁbrous pericarditis
and a cardiac conduction system [26]. Myocardial perfusion
abnormality may be related to scattered or diﬀuse ﬁbrosis
and contraction band necrosis due to vasospasm or repeated
focal ischemia [7, 27, 28]. When the severity of disease
advances, perfusion defects may become larger or might
be detected by an exercise stress protocol. However, in the
early stage, the abnormality might not be evident based on
conventional exercise-stress protocol. Vasodilator imaging,
currently using dipyridamole, adenosine triphosphate, and
adenosine, might be useful for detecting ischemia. However,
pharmacological vasodilator stress would be more appropri-
ate for detecting ischemia by atherosclerotic coronary steno-
sis, rather than by vasospastic microcirculation abnormal-
ity. Conversely, dipyridamole signiﬁcantly improved resting
201Tl myocardial perfusion: the mean number of segments
with perfusion defects decreased from resting condition
after dipyridamole [29]. The same group also revealed
short-term improvement in 201Tl myocardial perfusion with
nifedipine in patients with progressive systemic sclerosis
[23]. In contrast, ﬁxed perfusion defect, either scattered or
segmental, reﬂects myocardial ﬁbrosis, and stress-induced
ischemia reﬂects vasospasm of small coronary arteries or
coronary stenosis. Both ischemia and ﬁbrosis coexist in an
individual heart, and the induced ischemia may be reversible
and potentially treated by medications.
3.2. Left Ventricular Dysfunction in SSc. Resting left ventric-
ular ejection fraction (EF) and its response to exercise also
appeared to be unrelated to the ﬁndings on 201Tl scanning,
except for subtle abnormality [17]. However, 201Tl perfusion
defects appeared to be related to left ventricular function,
which showed that patients with perfusion defect had scores
above the median value. In contrast, several patients with
diﬀuse scleroderma had prominently abnormal EF at restInternational Journal of Rheumatology 3
Table 2: Comparison of low and high skin thickness score in patients and control subjects.
Control Low MRSS High MRSS P
(<10) (≥10)
N1 6 1 6 1 8
Age (years) 50 ±12 56 ±10 55 ±15 n.s.
Male:female 2:14 2:14 1:17 n.s.
MRSS — 4.0 ±2.51 9 .2 ±6.7 <.0001
Myocardial perfusion imaging
Induced ischemia 0 2 1 n.s.
Resting hypoperfusion 0 2 3 n.s.
Gated SPECT
Heart rate (/min) 65 ± 76 8 ±11 71 ±8n . s .
EF (%) 68 ± 97 3 ± 97 1 ±12 n.s.
EF <55% 0 (0%) 0 (0%) 2 (11%) n.s.
PFR (/sec) 2.46 ±0.45 2.76 ±0.44 2.74 ±0.53 n.s.
1/3 MFR (/sec) 1.52 ±0.25 1.57 ±0.31 1.25 ±0.42 .017
TPFR (msec) 166 ± 22 168 ±38 216 ±82 .015
TPFR/RR 0.18 ±0.02 0.19 ±0.04 0.26 ±0.09 .002
Adapted from the results of [30]
MRSS, modiﬁed Rodnan total skin thickness score;
EF, ejection fraction; PFR, peak ﬁlling rate; 1/3 MFR, one-third mean ﬁlling rate;
TPFR, time to PFR; TPFR/RR, TPFR divided by RR interval.
with further prominent deterioration during exercise [16].
Thus, a baseline decrease in left ventricular contractility may
be related to resting perfusion defects that reﬂect myocardial
ﬁbrosis.
In a Japanese population, we performed a stress 99mTc
methoxy-isobutyl-isonitrile (MIBI) study with ECG-gating
of 16 frames per cardiac cycle in 34 patients with SSc
[30]. Compared with Western studies as described above, in
contrast, only slight segmental defect and/or stress-induced
ischemia were observed by perfusion SPECT (Table 2). We
found a signiﬁcant relationship between diastolic abnormal-
ity and modiﬁed Rodnan total skin thickness score (MRSS)
[5, 31]. A decreased resting EF of less than 55% was found
in no patients in the low-MRSS group and in two patients
in the high-MRSS group. However, diastolic dysfunction was
observed in the high-MRSS group. The time to peak ﬁlling
rate diﬀered signiﬁcantly among the control, low-MRSS
and high-MRSS groups. Impaired relaxation and diastolic
asynchrony in SSc were also reported using radionuclide
angiography and echocardiography [32, 33].
Diastolic dysfunction as detected by either gated myocar-
dial perfusion imaging or radionuclide ventriculography was
not speciﬁc to the ﬁndings of SSc. Diastolic dysfunction
may have occurred even without any systolic dysfunction
in patients with ischemic heart disease, hypertrophic car-
diomyopathy, hypertensive heart diseases, and secondary
cardiomyopathies [34–37]. In patients with the clinical
syndrome of heart failure, determination of the presence and
severity of diastolic dysfunction is increasingly important
[14]. Complicated factors such as myocardial stiﬀness, wall
elasticity,compliance,incompleterelaxation,andventricular
pressure may be involved in diastolic dysfunction, and
a similar mechanism may also be at work in SSc. We
postulated that diastolic function was an early sign of cardiac
involvement, since it appeared even in patients with neither
perfusion abnormality nor systolic dysfunction.
Thus, we postulate that myocardial perfusion SPECT
abnormality is correlated to the severity of cardiac dys-
function. In mild dysfunctional patients, even when left
ventricular contractility is normal, diastolic dysfunction may
be related in some cases. A stress myocardial perfusion
scan might show reversible perfusion defect in patients with
mild to moderate severity. In patients with more advanced
severe dysfunction, ﬁxed perfusion defects and regional wall
motion abnormality would occur accompanied by global
decrease in EF. However, whether or not the slight degree
of perfusion abnormality and diastolic dysfunction would
result in further deterioration of cardiac function should be
investigated in a long-term follow-up study.
The reason for the relatively low incidence of perfusion
abnormality in our study might be explained by the selection
bias of our study population, which might not have included
the severer type of SSc. As for another possible reason,
it might have been caused by diﬀerences in the sex and
race of the patients, since ethnic diﬀerences have also been
demonstrated in a Japanese population [38, 39].
3.3. Additional Information by Quantitative Gated SPECT
Analysis. Our experience with SSc patients has shown that
large perfusion defects and induced ischemia do not seem
to be so common as described previously. Instead, small
regional abnormality has become evident by the help of
quantitative analysis. Current nuclear cardiology technology
uses sophisticated computer-aided diagnosis for quantiﬁca-
tion. As an example, a patient with SSc is shown in Figure 1.4 International Journal of Rheumatology
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Figure 1: A patient with SSc showing slight anteroseptal ischemia. Quantitative analyses of perfusion, defect scores, wall motion and
thickening showed signiﬁcant abnormality, which supported abnormality in this region (arrows). Diastolic dysfunction was observed even
at resting condition as shown by the blue arrow.
A 66-year old male patient diagnosed with dcSSc was
referred to our department for nuclear cardiology for the
purpose of evaluating possible cardiac involvement. His
onset of disease was Raynaud’s phenomenon 5 years ago
prior to his visit. Scleroderma progressed since 2 years ago
extendingfromhands,forearms,anteriorchesttoabdominal
skin, and the MRSS indicated moderate severity (score 25 of
51). Signiﬁcant pulmonary ﬁbrosis was observed by X-ray
computed tomography (CT). Myocardial perfusion SPECT
was performed with 99mTc MIBI using stress-rest protocol.
During exercise, only a slight decrease in perfusion was
observed in the apical anteroseptal walls. A polar map
display, with a 17-segment model overlaid, showed a local-
ized decrease in perfusion in the anteroseptal region. The
summedstressscoreandrestscorenamely,semi-quantitative
defect scores during exercise and at rest were 3 and 1,
which was judged as only a slight abnormality. In the polar
map, wall motion and systolic thickening were apparently
reducedintheanteroseptalregion,particularlyafterexercise.
A three-dimensional ventricular contour display showed
apical anterior hypokinesis. A volume curve by gated SPECT
showed characteristics of diastolic dysfunction. The time to
peakﬁllingrate(TPFR)asdeﬁnedfromthetimepointsfrom
end-systole to peak ﬁlling rate was prolonged to 352msec
(normal value for Japanese population: 159±26 msec (SD)).
The early diastolic parameter of 1/3 mean ﬁlling rate was
0.94/sec (normal value: 1.68 ± 0.30/sec)) [40]. Instead of
simply judging positive or negative perfusion defects, we
were able to deﬁnitely diagnose the abnormality in the
SPECT study by integrating various quantitative parameters.
3.4. Possible Options of Radiopharmaceuticals. Myocardial
perfusion imaging is fundamental for evaluating myocardial
damage. In addition, patients with SSc have a high frequency
of diastolic dysfunction and sympathetic abnormality as
shown by 123I-metaiodobenzylguanidine (MIBG) studiesInternational Journal of Rheumatology 5
[41, 42]. 123I-MIBG is known as an analogue of nore-
pinephrine and shares its metabolic pathways with cate-
cholamine uptake and excretion. Sympathetic abnormality
has been detected by decreased uptake and rapid clearance
from the heart. Initial experiences of MIBG support its
use in ischemic heart diseases, typically shown as regional
denervation of the heart in acute coronary syndromes
and cardiomyopathies. Currently, 123I-MIBG has been used
for patients with heart failure as well as neurological
disorders involving Lewy-body diseases [43–45]. It has
been understood that MIBG uptake reﬂects sympathetic
neuronal activity or norepinephrine contents, and increased
sympathetic activity drives results in rapid MIBG clearance.
Figure 2 shows a patient with normal myocardial perfusion
associated with severe decrease in MIBG activity. In this
patient, early and delayed heart-to-mediastinum average
count ratio (H/M) was 1.67 and 1.34, respectively (normal
values: 2.39 ± 0.21 and 2.49 ± 0.25, resp., [40]). MIBG
washout rate also increased to 33% (normal value was
<20% [46]). In concordance with the MIBG abnormalities,
some studies have indicated that autonomic dysfunction was
extremely common in patients with SSc. It was characterized
by parasympathetic impairment and marked sympathetic
overactivity, particularly in the early stage [47, 48]. However,
a cause and eﬀect relationship between autonomic derange-
ment and repeated myocardial damage has not been clearly
identiﬁed.
The use of MIBG imaging has also been validated by
a large prognostic multicenter trial in patients with heart
failure of New York Hear Association (NYHA) functional
class II/III and LVEF of 35% or less [49]. The two-year event
rate was 15% for H/M ≥1.60 and 37% for H/M <1.60. The
authors found that 123I-MIBG provided additional discrimi-
nation in analyses of interactions between B-type natriuretic
peptide, LVEF and H/M ratio. Although pathophysiological
evidences of heart failure in the study could not be readily
applicable to SSc patients, the MIBG imaging may provide
new insights into the nature and prognosis of myocardial
damage in SSc.
An article reported a case of systemic sclerosis with a
subacute episode of myocardial disease assessed by 111In-
antimyosin antibody, which was a marker of the myocardial
damage or necrosis [50]. However, antimyosin antibody
was considered to accumulate in ongoing myocardial injury
typically caused by ischemia or infarction, and thus it may
not be applicable for an early stage of systemic sclerosis.
4.PrognosticValueof NuclearCardiology
in SystemicSclerosis
Large-scale prospective cohort studies have been performed
extensively in the ﬁeld of coronary artery disease, although
such prognostic studies are still limited in patients with
SSc. However, it has been recognized that cardiopulmonary
involvement has been considered to be a poor prognostic
factor since renal involvement is no longer a major cause of
death in SSc, [7, 27, 51]. Steen and Medsger demonstrated
thatwhennaturalhistoryandtimingofsevereorganinvolve-
ments were analyzed in the dcSSc, the 9-year cumulative
survival rate of all patients with severe organ involvement
was 38%, compared with 72% in patients without such
involvement[52].Long-termprognosiswasfoundtobepoor
in patients with 201Tl perfusion defect. A study followed
up 48 patients who underwent a perfusion scan in the
1980s. Notably, the survival information over the last 10
years revealed that the size of the initial defect was the
best predictor of later adverse events compared with other
disease-related features. These kinds of long-term prognostic
study, which has been accumulating in the ﬁeld of coronary
artery disease, should also be conducted in SSc patients both
retrospectively and prospectively.
5.PracticalApproachesto Cardiac
Evaluationin SSc
Although we have focused on nuclear cardiology methods,
echocardiography remains the mainstream tool for heart
evaluation in SSc patients [6, 27, 53]. Diagnostic work-
ups in patients with SSc are summarized in Figure 3 from
the viewpoint of cardiac imaging. The ﬁrst step for the
diagnosis starts by careful evaluation of the history and
symptoms, followed by the physical examination including
skin sclerosis and possible organ involvements. The baseline
12-lead ECG and chest X-ray examination are standard
procedures for screening. When considering the possibility
of cardiac involvement, echocardiography, coupled with
Doppler if possible, would be the ﬁrst-line methodology
for cardiac functional evaluation. This approach would
show the presence of pericardial eﬀusion, right ventricular
involvement as well as left ventricular systolic and diastolic
function.
When cardiac abnormalities are suspected by the initial
screening tests, the next step would be diverse, depending
on the clinical problems in the individual patient. In
patientswithpulmonaryarterialhypertension(PAH),guide-
lines from both the American College of Chest Physicians
(ACCP)andEuropeanSocietyforPAHrecommendedchest-
X-ray, ECG and Doppler echocardiography as evidence-
based approaches [54, 55]. The prevalence of pulmonary
hypertension associated with scleroderma ranged from 4.9%
to 38% as written in the ACCP guidelines. In addition,
cardiac catheterization for the assessment of pulmonary
hypertension might still be required in some patients who
can beneﬁt from intervention. The appropriate evaluation
of PAH has practical values for guiding medical treatment,
as four sets of recommendations were formulated for SSc-
related PAH by EULAR scleroderma trials and their research
group [56]. The ACCP also revised the treatment algorithm
by taking into account recent developments in therapy
[57]. Nuclear cardiology has no validated role for this
purpose, although lung ventilation/perfusion may be evalu-
ated in chronic thromboembolic pulmonary hypertension,
and metabolism in the right ventricular overload [55, 58,
59]. Right ventricular function may also be evaluated by
echocardiography or gated blood-pool study [60]. However,6 International Journal of Rheumatology
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Adapted from [41].
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Figure 3: Possible roles of cardiac imaging modalities for diagnostic work-ups and followup in SSc. Abbreviations: ECG, electrocardio-
graphy; Cath., catheterization; MRI, magnetic resonance imaging; CT, computed tomography; SPECT, single-photon emission computed
tomography; PET, positron emission tomography.
when a major concern of the patient problem involves
induced myocardial ischemia, a stress nuclear study with
vasodilator or vasoconstrictor stressors would be the best
option for guiding management. If stress-induced large
perfusion defects were found in the stress study, coronary
work-ups with CT angiography using contrast media would
be selected. Coronary evaluation may not be indicated when
the perfusion defect is relatively small and microvascular
origin is more likely. When myocardial ﬁbrosis is suspected
based on the ventricular contractility, regional wall motion
or diastolic function, the severity might be evaluated by
a nuclear study. Recently, using delayed enhanced mag-
netic resonance imaging (MRI), several studies successfully
identiﬁed myocardial ﬁbrosis in a signiﬁcant percentage of
patients with SSc [27, 61, 62]. The SPECT or positron
emission tomography (PET) may identify larger defectsInternational Journal of Rheumatology 7
and/or associated ischemia. No comparative study for their
eﬀectiveness has been performed to date.
According to our study, it is apparent that all patients
diagnosed with SSc are not indicated for a SPECT study.
Based on our study population, it is noteworthy that patients
with the lcSSc type or MRSS less than 10 showed neither
signiﬁcant perfusion defect nor ventricular dysfunction
(Table 2). Therefore,we tentatively recommend a myocardial
perfusion study in patients with dcSSc type and/or MRSS
greater than 10, when the patient is suspected of having
cardiac abnormality [30, 41]. Belloli et al. studied potential
risk factors for microvascular involvement and found that
perfusion defects were related to skin scores, digital ulcers,
and esophageal involvement, and these patients might
warrant screening for myocardial involvement [24]. Thus,
patients with SSc who have a history of chest symptoms,
conduction abnormality or arrhythmia on ECG, and wall
motionabnormalityandthosewhohaveﬁndingsofmultiple
organ complications would be potential candidates for
myocardial SPECT imaging.
The best diagnostic approach or decision tree for cardiac
evaluation has not been deﬁned yet, although chest X-
ray and echocardiography would be the ﬁrst-step imaging
method readily available in any hospital. While several
possible diagnostic approaches have been proposed, some
of them might have practical values for diagnosis, and
others may provide pathophysiological insight or prognostic
information. The determination of the appropriate role of
imaging is of great concern in the era of multimodality
cardiac imaging.
6. Conclusion
Myocardial involvement as part of diﬀuse organ ﬁbrosis and
vascular changes is commonly observed in SSc. Even when
severe ﬁbrosis as evidenced by myocardial perfusion defects
isnotobserved,perfusionreservesorfunctionalabnormality
might be detected as an earlier sign of myocardial damage.
Theaidofcomputer-assisteddiagnosiswillenhancethediag-
nostic ability for identifying abnormalities. The relationship
of nuclear imaging and prognosis should be evaluated to
conﬁrm the role of functional imaging for patients with SSc.
Finally, the roles or eﬀectiveness of various current imaging
modalities remain to be deﬁned.
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